Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced that CEO Ilya Rachman and CFO Gabriel Morris will present a company overview at the ThinkEquity Conference on October 26, 2022, at 2:00 PM ET. The presentation will highlight milestones achieved to kick off two clinical trials for IMX-110, which is currently in Phase 1b/2a trials with orphan drug designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma. Expectations are for clinical trial data to be released in Q1 2023.
Immix Biopharma (Nasdaq: IMMX) has expanded its clinical trial consortium by adding four additional oncology sites to enhance the testing of its drug IMX-110 for soft tissue sarcoma. The lead site in California has historically enrolled 2-3 patients monthly. As part of the trial, patients will receive CT scans every eight weeks to monitor tumor response, with data release commencing in Q1 2023. The FDA has granted orphan drug designation and rare pediatric disease designation for IMX-110, enabling potential fast track and priority review upon marketing approval.
Immix Biopharma (Nasdaq: IMMX) has successfully completed Good Manufacturing Practice (GMP) manufacturing of IMX-110, a drug candidate for clinical trials. This scaled-up process will support two upcoming clinical trials: one for monotherapy in soft tissue sarcoma and another combining IMX-110 with BeiGene's anti-PD-1 tislelizumab for advanced solid tumors. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, enabling it to benefit from expedited review processes. The company aims to initiate these trials in 2022.
Immix Biopharma (Nasdaq: IMMX) announced promising interim results for IMX-110 from a Soft Tissue Sarcoma (STS) mice study. After one treatment cycle, IMX-110 demonstrated a 75% survival rate compared to 0% for Trabectedin, an FDA-approved drug. This positions IMX-110 favorably in a potential $3 billion STS market projected to reach $6.5 billion by 2030. CEO Ilya Rachman expressed optimism ahead of two clinical trials for IMX-110 set to begin in 2022.
Immix Biopharma (Nasdaq: IMMX) has authorized a $1 million stock buyback program to enhance shareholder value. The company, with approximately $18 million in cash and equivalents as of December 31, 2021, and 13.9 million shares outstanding, aims to execute purchases based on market conditions and regulatory considerations. CEO Ilya Rachman expressed confidence in reaching critical milestones with their lead asset, IMX-110, while emphasizing alignment with shareholder interests.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced its Milestone Day Event on April 5, 2022, showcasing its drug development progress and the company’s financial position after raising $24.2 million in its IPO. Management outlined plans to begin two clinical trials in 2022, specifically for its lead asset, IMX-110, which targets oncology and immuno-dysregulated diseases. The event highlighted the company’s unique Tissue-Specific Therapeutics (TSTx) approach and its orphan drug designation for soft tissue sarcoma. For more information, visit immixbio.com.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced plans for the IMMX Milestone Day Event on April 5, 2022, where management will discuss the company’s financial position, milestones, and market opportunities amid current volatility. The company raised $24.2 million from its December 2021 IPO and aims to initiate two clinical trials in 2022. CEO Ilya Rachman expressed confidence in achieving planned milestones with the capital raised, emphasizing the company's strategy to leverage market conditions for growth.
Immix Biopharma (Nasdaq: IMMX) has initiated Good Manufacturing Practice (GMP) manufacturing for IMX-120, a biologic targeting inflammatory bowel disease (IBD). The company plans to file an Investigational New Drug (IND) application for IMX-120 in 2023, marking an important milestone for future clinical trials. The IBD market is projected to grow from $18.4 billion in 2019 to $21.4 billion by 2024, underscoring the potential market opportunity for IMX-120. This development highlights ImmixBio's commitment to advancing treatment options in the biopharmaceutical sector.
Immix Biopharma has hosted an Investors Day event on February 1, 2022, where management responded to top-voted questions from verified shareholders. The session highlighted the company’s commitment to transparency and ongoing communication with investors. ImmixBio is focused on its lead asset, IMX-110, currently in Phase 1b/2a clinical trials for soft tissue sarcoma and rhabdomyosarcoma, supported by orphan drug and rare pediatric designations by the FDA.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced the initiation of Good Manufacturing Practice (GMP) scale-up for IMX-110, marking a significant step toward accelerating two clinical trials planned for 2022. The first trial focuses on IMX-110 monotherapy for soft tissue sarcoma, while the second tests the combination of IMX-110 with BeiGene's anti-PD-1 tislelizumab for advanced solid tumors. IMX-110 has received orphan drug and rare pediatric disease designations from the FDA, enabling fast-track review for its marketing approval.